Cytokines as clinical adjuvants: how far are we?

References

• Voss G, Villinger E Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS. AIDS 14\(Suppl. 3), S153—S165 (2000).
   Google Scholar
• Vonderheide RII, Dutcher JP, Anderson JE et al. Phase I study of recombinant human CD40 ligand in cancer patients. j Clin. Oncol 1913,3280–3287 (2001).
   Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ et al CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 969, 2917–2924 (2000).
   Google Scholar
• von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 75,1181-1191 (2001).
   Google Scholar
• Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr. Opin. Mal Thec 34, 407–412 (2001).
   Google Scholar
• Agarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology ffluntingt) 169, 1177–1187 (2002).
   Google Scholar
• Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev. 132, 185–193 (2002).
   Google Scholar
• Miller SJ. The use of interleukins for advanced melanoma. Skin Therapy. Lett. 64, 3–5 (2001).
   Google Scholar
• Weiss L. Immune-based therapies and HIV infection. Ann. Merl Interne (Paris) 1534, 227–236 (2002).
   Google Scholar
• Pizza P, Ferrantini M, Capone I et al. Cytokines as natural adjuvants for vaccines: where are we now? Wends Immunol 238, 381–383 (2002).
   Google Scholar
• Forni G, Boggio K. Cytokine gene-engineered vaccines. CI.117: Opin. Mal Ther. 11,34-38 (1999).
   Google Scholar
• Jefford M, Maraskovsky E, Cebon J et al. The use of dendritic cells in cancer therapy. Lancet Oncol 26,343–353 (2001).
   Google Scholar
• Nawrocki S, Mackiewicz A. Genetically modified tumour vaccines — where we are today. Cancer Brat. Rev. 251,29–46 (1999).
   Google Scholar
• Toungouz M, Libin M, Bulte F et al. Transient expansion of peptide-specific lymphocytes producing IFN-y after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. j Leukoc. 696,937–943 (2001).
   Google Scholar
• Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. Clin. Invest 10912,1519–1526 (2002).
   Google Scholar
• Buchan GS, Young SL, Lockhart EA et al. Targeting early events in T-cell activation to construct improved vaccines. Mal Immunol 379,545–552 (2000).
   Google Scholar
• Antia R, Pilyugin SS, Ahmed R. Models of immune memory: on the role of cross-reactive stimulation, competition and homeostasis in maintaining immune memory. Proc. Natl Acad. Sci.USA 9525, 14926–14931 (1998).
   Google Scholar
• Becker TC, Wherry EJ, Boone D et al. interleukin-15 is required for proliferative renewal of virus-specific memory CD8 T-cells.J. Exp. Med 19512,1541–1548 (2002).
   Google Scholar
• Hayashi K, Fukuda Y, Nakano I et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 66,677–681 (2000).
   Google Scholar
• Hatzakis A, Gargalianos P, Kiosses V et al. Low-dose IFN-a monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. .1. Interferon Cytokine Res. 2110,861–869 (2001).
   Google Scholar
• Smith IKA. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 15 (Suppl. 2), S28—S35 (2001).
   Google Scholar
• Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4 T-cells in HIV-1-infected adults treated with growth hormone. AIDS168, 1103–1111 (2002).
   Google Scholar
• Chlabicz S, Grzeszczuk A, Lapinski TVV. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: the effect of interferon-alpha therapy. Med. Li. Monit. 85, CR379—CR383 (2002).
   Google Scholar
• Belardelli F, Ferrantini M, Proietti E et al. Interferon-a in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 132,119–134 (2002).
   Google Scholar
• Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control 94,293–304 (2002).
   Google Scholar
• Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol 293\(Suppl. 7), 18–26 (2002).
   Google Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. 262,3-11 (1991).
   Google Scholar
• Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol 111,76–81(1999).
   Google Scholar
• Tough DF, Sun S, Zhang X et al. Stimulation of naive and memory T-cells by cytokines. Immunol Rev 170,39–47 (1999).
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M et al. Cellular responses to interferon-gamma. Ann. Rev Immunol 15,749–795 (1997).
   PubMed Web of Science ®Google Scholar
• Reiter Z. Interferon-a major regulator of natural killer cell-mediated cytotoxicity. Interferon Res. 134,247–257 (1993).
   Google Scholar
• Luft T, Luetjens P, Hochrein H et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int. Immunol 144,367–380 (2002).
   Google Scholar
• Montoya M, Schiavoni G, Mattei F et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. B/ooc/999, 3263–3271 (2002).
   Google Scholar
• Oritani K, Kincade PW, Zhang C et al. Type I interferons and limitin: a comparison of structures, receptors and functions. Cytokine Growth Factor Rev. 124, 337–348 (2001).
   Google Scholar
• Dijkmans R, Billiau A. Interferon gamma: a master key in the immune system. CI.117: Opin. Immunol 12,269–274 (1988).
   Google Scholar
• Vogel SN, Havell EA and Spitalny GL. Monoclonal antibody-mediated inhibition of interferon-gamma-induced macrophage antiviral resistance and surface antigen expression. j Immunol 1368,2917–2923 (1986).
   Google Scholar
• Younes HM, Amsden BG. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. Pharm. Sci. 911,2–17 (2002).
   Google Scholar
• Sondak VK. Use of adjuvant therapy in cutaneous melanoma. Expert. Rev Anticancer Ther. 13,421–426 (2001).
   Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage JIB-ITT melanoma: results of intergroup trial E1694/59512/C509801. Clin. Oncol 199,2370–2380 (2001).
   Google Scholar
• Kirkwood JM, Ibrahim J, Lawson DH et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Co-operative Oncology Group Phase II Trial E2696.J Clin. Oncol 195, 1430–1436 (2001).
   Google Scholar
• Damasio EE, Clavio M, Masoudi B et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur. Haematol 641,47–52 (2000).
   Google Scholar
• Wu CJ, Yang XF, McLaughlin S et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. j Clin. Invest1065,705–714 (2000).
   Google Scholar
• Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T-lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 69, 1018–1023 (2000).
   Google Scholar
• Hejny C, Sternberg P, Lawson DH et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am. Ophthalmol 1316,782–787 (2001).
   Google Scholar
• Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 1051–1052,45-55 (2001).
   Google Scholar
• Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 3589285,866–869 (2001).
   Google Scholar
• Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon CL-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Co-operative Group. j Clin. Oncol 164, 1425–1429 (1998).
   Google Scholar
• Bajetta E, Del Vecchio M, Vitali M et al. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy metastatic melanoma. Tumor] 874, 219–222 (2001).
   Google Scholar
• Shepherd FA. Alternatives to chemotherapy and radiotherapy in the treatment of small.
   Google Scholar
• Heintges T, Petry W, Kaldewey M et al. Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with.
   Google Scholar
• Goldwater PN. Randomized comparative trial of interferon-alpha versus placebo in (1994).
   Google Scholar
• Ozener C, Fak AS, Avsar E et al. The effect of alpha interferon therapy and shortinterval intradermal administration on response to hepatitis B vaccine inhaemodialysis patients. Nephrol. Dial.Transplant. 145, 1339–1340 (1999).
   Google Scholar
• Quiroga JA, Castillo I, Porres JC et al. Recombinant gamma-interferon as.
   Google Scholar
• Ahlers JD, Belyakov IM, Matsui S et al. Mechanisms of cytokine synergy essential for.
   Google Scholar
• Musch E, Hogemann B, Gerritzen A et al. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic.
   Google Scholar
• Kakumu S, Ishikawa T, Mizokami M et al Treatment with human gamma interferon of chronic hepatitis B: comparative study.
   Google Scholar
• Kamal SM, Fehr J, Roesler B et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Castmentemlogy1234, 1070–1083 (2002).
   Google Scholar
• Emilie D, Burgard M, Lascoux-Combe C et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS1511, 1435–1437 (2001).
   Google Scholar
• Haas DW, Lavelle J, Nadler JP et al. A randomized trial of interferon alpha therapy for HR/ Type 1 infection. AIDS Res. Hum. Retrovithses 163, 183–190 (2000).
   Google Scholar
• Rivero J, Fraga M, Cancio I et al. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy102, 107–113 (1997).
   Google Scholar
• Frissen PH, de Wolf F, Reiss P et al High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus Type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. Infect. Dis. 1763, 811–814 (1997).
   Google Scholar
• Krown SE. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. .1. Interferon Cytokine Res. 184, 209–214 (1998).
   Google Scholar
• Di M, Thevenot, V. Colin, T. JF et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Castroentemlogy1236, 1812–1822 (2002).
   Google Scholar
• Rockstroh JK, Mudar M, Lichterfeld M et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AID51615, 2083–2085 (2002).
   Google Scholar
• Matutes E, Taylor GP, Cavenagh J et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. BE Haematol 1133, 779–784 (2001).
   Google Scholar
• Bukowski RM, Olencki T, Wang Q et al. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. Immunother. 204, 301–311 (1997).
   Google Scholar
• Mocellin S, Rossi CR, Lise M et al. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother. 51(11-12), 583–595 (2002).
   Google Scholar
• Brod SA. Ingested Type I interferon: state of the art as treatment for autoimmunity. Exp. Biol. Med. (Maywood) 22711, 981–988 (2002).
   Google Scholar
• Stull DM. Colony-stimulating factors: beyond the effects on hematopoiesis. Am. Health Syst.Pharm. 597\(Suppl. 2), S12—S20 (2002).
   Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. CL117: Opin. Hematol 73, 168–173 (2000).
   Google Scholar
• Burdach S, Nishinakamura R, Dirksen U et al. The physiologic role of interleukin-3, interleukin-5, granulocyte-macrophage colony-stimulating factor and the beta c receptor system. CLI17: Opin. Hematol 53, 177–180 (1998).
   Google Scholar
• Pulendran B, Banchereau J, Maraskovsky E et al. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 221, 41–47 (2001).
   Google Scholar
• Spitler LE. Adjuvant therapy of melanoma. Oncology (Huntingt) 161 (Suppl. 1), 40–48 (2002).
   Google Scholar
• Metcalf D. Cellular hematopoiesis in the twentieth century. Sendn. Hematol 364 (Suppl. 7), 5–12 (1999).
   Google Scholar
• Anderson JE, Appelbaum FR. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. CUI7: Opin. Hematol 13, 203–209 (1994).
   Google Scholar
• Follador I, Araujo C, Orge G et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte—macrophage colony -stimulating factor. Vaccine 209–10, 1365–1368 (2002).
   Google Scholar
• Looney RJ, Hasan MS, Coffin D et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CDT-T-cells and primary immune response and evaluation of GM-CSF as an adjuvant. Clin. Immunol 211, 30–36 (2001).
   Google Scholar
• Sudhagar K, Chandraselcar S, Rao MS et al. Effect of granulocyte macrophage colony stimulating factor on hepatitis-B vaccination in haemodialysis patients. J. Assoc Physicians India 476, 602–604 (1999).
   Google Scholar
• Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. NEphml. 542, 138–142 (2000).
   Google Scholar
• Anandh U, Bastani B and Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am NEphml. 201, 53–56 (2000).
   Google Scholar
• Hasan MS, Agosti JM, Reynolds KK et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. j Infect. Dis. 1806, 2023–2026 (1999).
   Google Scholar
• Pauksen K, Linde A, Hammarstrom V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis. 302, 342–348 (2000).
   Google Scholar
• Buchsel PC, Forgey A, Grape FB et al. Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. Clin. j Oncol NUTS. 64, 198–205 (2002).
   Google Scholar
• Angel JB, High K, Rhame F et al Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS144, 387–395 (2000).
   Google Scholar
• Weber J, Sondak VK, Scotland R et al Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer971, 186–200 (2003).
   Google Scholar
• Kawai K, Tani K, Asano S et al EY viva gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines. Mo/. Um/. 42, 43–46 (2000).
   Google Scholar
• Hunger RE, Brand CU, Streit M et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol 103, 161–167 (2001).
   Google Scholar
• Schaed SG, Klimek VM, Panageas KS et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor and QS-21 as immunological adjuvants. Clin. Cancer Res. 85,967-972 (2002).
   Google Scholar
• Simmons SJ, Tjoa BA, Rogers M et al. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. Prostate 394, 291–297 (1999).
   Google Scholar
• Knutson KL, Schiffman K, Cheever MA et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 85, 1014–1018 (2002).
   Google Scholar
• Ramanathan RK, Potter DM, Belani CP et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. j Clin. Oncol 2021,4313–4318 (2002).
   Google Scholar
• Kusakabe K, Xin KQ, Katoh H et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J. Immunol 1646, 3102–3111 (2000).
   Google Scholar
• Sosman JA, Hank JA, Moore KH et al. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. Cancer Invest 91,35–48 (1991).
   Google Scholar
• Mier JW, Aronson FR, Numerof RP et al. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res. 76, 459–476 (1988).
   Google Scholar
• Lissoni P Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer 1 ScL Am. 3\(Suppl. 1), S115—S120 (1997).
   Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol 133, 688–696 (1995).
   Google Scholar
• Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 2104, 474–484 (1989).
   Google Scholar
• Atkins MB. Interleukin-2: clinical applications. Semin. Oncol 293\(Suppl. 7), 12–17 (2002).
   Google Scholar
• Dutcher J, Atkins MB, Margolin K et al. Kidney cancer: the Cytokine Working Group experience (1986–2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med. Oncol 183, 209–219 (2001).
   Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer 1 Sc]. Arn. 6\(Suppl. 1), S55—S57 (2000).
   Google Scholar
• Atkins MB, Kunkel L, Sznol M et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer 1 Sc]. Am. 6\(Suppl. 1), S11—S14 (2000).
   Google Scholar
• Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol 169, 2921–2929 (1998).
   Google Scholar
• Du Bois JS, Trehu EG, Mier JW et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol 153,1052–1062 (1997).
   Google Scholar
• Sosman JA, Bartemes K, Offord KP et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin. Cancer Res. 18, 805–812 (1995).
   Google Scholar
• Sosman JA, Fisher SG, Kefer C et al. A Phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann. Oncol 55,447–452 (1994).
   Google Scholar
• Ghosh AK, Smith NK, Prendiville J et al. A Phase I study of recombinant human interleukin-4 administered by the iv. and sc. route in patients with advanced cancer: immunological studies. Eur. Cytokine Netw 43,205–211 (1993).
   Google Scholar
• Smith KA, Jacobson EL, Emert R et al. Restoration of immunity with interleukin-2 therapy. AIDS Read. 98,563–572 (1999).
   Google Scholar
• Davey RT, Jr., Chaitt DG, Piscitelli SC et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus Type 1-infected persons. J. Infect. Dis 1754,781–789 (1997).
   Google Scholar
• Emery S, Capra WB, Cooper DA et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus Type 1 disease. J. Infect. Dis. 1822,428–434 (2000).
   Google Scholar
• Davey RT, Jr., Chaitt DG, Albert JM et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 out -patient therapy for early human immunodeficiency virus Type 1 infection. J. Infect. Dis. 1794,849–858 (1999).
   Google Scholar
• Lalezari JP, Beal JA, Ruane PJ et al. Low-dose daily sc. interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clin. Trials 13,1–15 (2000).
   Google Scholar
• Paredes R, Lopez Benaldo de Quiros JC, Fernandez-Cruz E et al. The potential role of interleukin-2 in patients with HIV infection. AIDS Rev 41,36–40 (2002).
   Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev Immunol 32, 133–146 (2003).
   Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunityand immunotherapy. Cytokine Growth Factor Rev 132,155–168 (2002).
   Google Scholar
• Ansari AA, Mayne AE, Sundstrom JB et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J. Viral 764, 1731–1743 (2002).
   Google Scholar
• Hoffman SL, Crutcher JM, Puri SK et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 31,80-83 (1997).
   Google Scholar
• Robertson MJ, Cameron C, Atkins MB et al. Immunological effects of interleukin-12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 51,9-16 (1999).
   Google Scholar
• Atkins MB, Robertson MJ, Gordon M et al. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res. 33,409-417 (1997).
   Google Scholar
• Lotze MT, Hellerstedt B, Stolinski L et al. The role of interleukin-2, interleukin-12 and dendritic cells in cancer therapy. Cancer 1 Sci. Am 3\(Suppl. 1) S109—S114 (1997).
   Google Scholar
• Rook AH, Wood GS, Yoo EK et al. Interleukin-12 therapy of cutaneous T—cell lymphoma induces lesion regression and cytotoxic T-cell responses. B1ooc1943, 902–908 (1999).
   Google Scholar
• Jacobson MA, Spritzler J, Landay A et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS168, 1147–1154 (2002).
   Google Scholar
• Zeuzem S, Hopf U, Carreno V et al. A Phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology294,1280–1287 (1999).
   Google Scholar
• Gajewski TF, Fallarino F, Ashikari A et al. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin-12. Clin. Cancer Res. 73(Suppl.) 895s-901s (2001).
   Google Scholar
• Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. B/ooc/907,2541–2548 (1997).
   Google Scholar
• Motzer RJ, Rakhit A, Thompson JA et al. Randomized multicenter Phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J. Interferon Cytokine Res. 214, 257–263 (2001).
   Google Scholar
• Motzer RJ, Rakhit A, Schwartz LH et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 45,1183-1191 (1998).
   Google Scholar
• Gollob JA, Mier JW, Veenstra K et al. Phase I trial of twice-weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin. Cancer Res. 65,1678-1692 (2000).
   Google Scholar
• Mortarini R, Born i Tragni, A. G et al. Peripheral burst of tumor-specific cytotoxic T-lymphocytes and infiltration of metastatic lesions by memory CD8+ T-cells in melanoma patients receiving interleukin-12. Cancer Res. 6013,3559–3568 (2000).
   Google Scholar
• Bajetta E, Del Vecchio M, Mortarini R et al. Pilot study of sc. recombinant human interleukin-12 in metastatic melanoma. Clin. Cancer Res. 41,75-85 (1998).
   Google Scholar
• Rook AH, Zaki MH, Wysocka Met al. The role for interleukin-12 therapy of cutaneous T-cell lymphoma. Ann. NY Acad. Sci 941, 177–184 (2001).
   Google Scholar
• Kang WK, Park C, Yoon HL et al. interleukin-12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a Phase I study. Hum. Gene Ther. 126,671-684 (2001).
   Google Scholar
• O'Neill E, Martinez I, Villinger F et al. Protection by SW VLP DNA Prime/protein boost following mucosal SW challenge is markedly enhanced by IL-12/GM-CSF co-administration. J. Med. Primatol 314–5,217–227 (2002).
   Google Scholar
• van der Meide PH, Villinger F, Ansari AA et al. Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 in Rhesus macaques. Vaccine 2017–18,2296–2302 (2002).
   Google Scholar
• Hedlund J, Langer B, Konradsen HB et al. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 201–2,164–169 (2001).
   Google Scholar
• Buchanan RM, Briles DE, Arulanandam BP et al. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 1915–16,2020-2028 (2001).
   Google Scholar
• Radcliff FJ, Caruso DA, Koina C et al. Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. BE .thematol 1191,204–211 (2002).
   Google Scholar
• Maraskovsky E, Daro E, Roux E et al. In vivo generation of human dendritic cell subsets by F1t3 ligand. B/ooc/963,878–884 (2000).
   Google Scholar
• Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/I[ trial. Cancer Immunol Immunother. 5111–12, 637–644 (2002).
   Google Scholar
• Merad M, Angevin E, Wolfers J et al. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). Immunother. 233,369–378 (2000).
   Google Scholar
• Onaitis M, Kalady ME, Pruitt S et al. Dendritic cell gene therapy. Surg. Oncol. Clin. N. A117. 113,645-660 (2002).
   Google Scholar
• Pecher G, Haring A, Kaiser L et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol Immunother. 5111–12, 669–673 (2002).
   Google Scholar
• McCluskie MJ, Weeratna RD. Novel adjuvant systems. C1.117: Drug Targets. Infect. Disord. 13,263-271 (2001).
   Google Scholar
• Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 20,2905491,486–492 (2000).
   Google Scholar
• Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in thelife and death of lymphocytes: implications for immunotherapy. Immunity142, 105–110 (2001).
   Google Scholar
• Deeks SG, Wagner B, Anton PA et al. A Phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 56,788–797 (2002).
   Google Scholar
• Yee C, Thompson JA, Byrd D et al. Adoptive T-cell therapy using antigen-specific CD8* T-cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration and antitumor effect of transferred T-cells. Proc. Natl Acad. Sri. USA 9925, 16168–16173 (2002).
   Google Scholar
• Zitvogel L, Couderc B, Mayordomo JI et al. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann. NY Acad. Sci 795,284–293 (1996).
   Google Scholar
• Kenney RT, Sacks DL, Sypek JP et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a Primate model of cutaneous leishmaniasis. Immunol. 163,4481–4488 (1999).
   Web of Science ®Google Scholar